Eli Lilly intends to invest $27 billion in constructing four new manufacturing plants in the United States in response to tariff threats from the Trump administration on pharmaceutical imports. This initiative is anticipated to generate around 3,000 high-skilled positions and 10,000 construction jobs. CEO David Ricks highlighted the significance of maintaining policies that facilitate such investments. The company foresees the new manufacturing sites becoming operational within five years, following discussions with various states regarding their locations.